234 related articles for article (PubMed ID: 36555443)
21. Analysis of the Phenotype Differences in Siblings with Alkaptonuria.
Zatkova A; Olsson B; Ranganath LR; Imrich R
Metabolites; 2022 Oct; 12(10):. PubMed ID: 36295892
[TBL] [Abstract][Full Text] [Related]
22. Identification of Potential Inhibitors for the Treatment of Alkaptonuria Using an Integrated In Silico Computational Strategy.
Zaib S; Rana N; Hussain N; Ogaly HA; Dera AA; Khan I
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985595
[TBL] [Abstract][Full Text] [Related]
23. Alkaptonuria in Turkey: Clinical and molecular characteristics of 66 patients.
Kisa PT; Gunduz M; Dorum S; Uzun OU; Cakar NE; Yildirim GK; Erdol S; Hismi BO; Tugsal HY; Ucar U; Gorukmez O; Gulten ZA; Kucukcongar A; Bulbul S; Sari I; Arslan N
Eur J Med Genet; 2021 May; 64(5):104197. PubMed ID: 33746036
[TBL] [Abstract][Full Text] [Related]
24. The human gene for alkaptonuria (AKU) maps to chromosome 3q.
Janocha S; Wolz W; Srsen S; Srsnova K; Montagutelli X; Guénet JL; Grimm T; Kress W; Müller CR
Genomics; 1994 Jan; 19(1):5-8. PubMed ID: 8188241
[TBL] [Abstract][Full Text] [Related]
25. Alkaptonuria: From Molecular Insights to a Dedicated Digital Platform.
Milella MS; Geminiani M; Trezza A; Visibelli A; Braconi D; Santucci A
Cells; 2024 Jun; 13(12):. PubMed ID: 38920699
[TBL] [Abstract][Full Text] [Related]
26. Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria.
Ranganath LR; Milan AM; Hughes AT; Khedr M; Davison AS; Shweihdi E; Norman BP; Hughes JH; Bygott H; Luangrath E; Fitzgerald R; Psarelli EE; van Kan C; Laan D; Olsson B; Rudebeck M; Mankowitz L; Sireau N; Arnoux JB; Le Quan Sang KH; Jarvis JC; Genovese F; Braconi D; Santucci A; Zatkova A; Glasova H; Stančík R; Imrich R; Rhodes NP; Gallagher JA
J Inherit Metab Dis; 2020 Jul; 43(4):737-747. PubMed ID: 31609457
[TBL] [Abstract][Full Text] [Related]
27. Homogentisate 1,2 dioxygenase is expressed in brain: implications in alkaptonuria.
Bernardini G; Laschi M; Geminiani M; Braconi D; Vannuccini E; Lupetti P; Manetti F; Millucci L; Santucci A
J Inherit Metab Dis; 2015 Sep; 38(5):807-14. PubMed ID: 25762405
[TBL] [Abstract][Full Text] [Related]
28. A novel ex vivo organotypic culture model of alkaptonuria-ochronosis.
Tinti L; Spreafico A; Chellini F; Galeazzi M; Santucci A
Clin Exp Rheumatol; 2011; 29(4):693-6. PubMed ID: 21813063
[TBL] [Abstract][Full Text] [Related]
29. Expression of tyrosine pathway enzymes in mice demonstrates that homogentisate 1,2-dioxygenase deficiency in the liver is responsible for homogentisic acid-derived ochronotic pigmentation.
Wilson PJM; Ranganath LR; Bou-Gharios G; Gallagher JA; Hughes JH
JIMD Rep; 2021 Mar; 58(1):52-60. PubMed ID: 33728247
[TBL] [Abstract][Full Text] [Related]
30. Alkaptonuria, ochronosis, and ochronotic arthropathy.
Mannoni A; Selvi E; Lorenzini S; Giorgi M; Airó P; Cammelli D; Andreotti L; Marcolongo R; Porfirio B
Semin Arthritis Rheum; 2004 Feb; 33(4):239-48. PubMed ID: 14978662
[TBL] [Abstract][Full Text] [Related]
31. Founder effects of the homogentisate 1,2-dioxygenase (HGD) gene in a gypsy population and mutation spectrum in the gene among alkaptonuria patients from India.
Danda S; Mohan S; Devaraj P; Dutta AK; Nampoothiri S; Yesodharan D; Phadke SR; Jalan AB; Thangaraj K; Verma IC; Danda D; Jebaraj I
Clin Rheumatol; 2020 Sep; 39(9):2743-2749. PubMed ID: 32212000
[TBL] [Abstract][Full Text] [Related]
32. Urine homogentisic acid and tyrosine: simultaneous analysis by liquid chromatography tandem mass spectrometry.
Hughes AT; Milan AM; Christensen P; Ross G; Davison AS; Gallagher JA; Dutton JJ; Ranganath LR
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul; 963():106-12. PubMed ID: 24952314
[TBL] [Abstract][Full Text] [Related]
33. Homogentisate 1,2-dioxygenase (HGD) gene variants, their analysis and genotype-phenotype correlations in the largest cohort of patients with AKU.
Ascher DB; Spiga O; Sekelska M; Pires DEV; Bernini A; Tiezzi M; Kralovicova J; Borovska I; Soltysova A; Olsson B; Galderisi S; Cicaloni V; Ranganath L; Santucci A; Zatkova A
Eur J Hum Genet; 2019 Jun; 27(6):888-902. PubMed ID: 30737480
[TBL] [Abstract][Full Text] [Related]
34. Alkaptonuria: Current Perspectives.
Zatkova A; Ranganath L; Kadasi L
Appl Clin Genet; 2020; 13():37-47. PubMed ID: 32158253
[TBL] [Abstract][Full Text] [Related]
35. Variant Analysis of Alkaptonuria Families with Significant Founder Effect in Jordan.
Khalil R; Ali D; Mwafi N; Alsaraireh A; Obeidat L; Albsoul E; Al Sbou' I
Biomed Res Int; 2021; 2021():1515641. PubMed ID: 34235214
[TBL] [Abstract][Full Text] [Related]
36. An update on molecular genetics of Alkaptonuria (AKU).
Zatkova A
J Inherit Metab Dis; 2011 Dec; 34(6):1127-36. PubMed ID: 21720873
[TBL] [Abstract][Full Text] [Related]
37. Natural history of alkaptonuria revisited: analyses based on scoring systems.
Ranganath LR; Cox TF
J Inherit Metab Dis; 2011 Dec; 34(6):1141-51. PubMed ID: 21748407
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of antioxidant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model.
Tinti L; Spreafico A; Braconi D; Millucci L; Bernardini G; Chellini F; Cavallo G; Selvi E; Galeazzi M; Marcolongo R; Gallagher JA; Santucci A
J Cell Physiol; 2010 Oct; 225(1):84-91. PubMed ID: 20648626
[TBL] [Abstract][Full Text] [Related]
39. Exacerbation of the ochronosis of alkaptonuria due to renal insufficiency and improvement after renal transplantation.
Introne WJ; Phornphutkul C; Bernardini I; McLaughlin K; Fitzpatrick D; Gahl WA
Mol Genet Metab; 2002; 77(1-2):136-42. PubMed ID: 12359141
[TBL] [Abstract][Full Text] [Related]
40. Homogentisic acid induces cytoskeleton and extracellular matrix alteration in alkaptonuric cartilage.
Galderisi S; Cicaloni V; Milella MS; Millucci L; Geminiani M; Salvini L; Tinti L; Tinti C; Vieira OV; Alves LS; Crevenna AH; Spiga O; Santucci A
J Cell Physiol; 2021 Aug; 236(8):6011-6024. PubMed ID: 33469937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
